CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Overview of attention for article published in Frontiers in oncology, December 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 6 X users

patent: 3 patents

Citations

dimensions_citation: 56 Dimensions

Readers on

mendeley: 67 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 16,258 followers.

RT @FrontOncology: New research: CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refra…

08 Jan 2020

Reply Repost Favourite

New research: CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma: Background: The therapeutic efficacy of chimeric antigen… https://t.

08 Jan 2020

Reply Repost Favourite

RT @CARTTherapy: CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Ce…

28 Dec 2019

Reply Repost Favourite

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma https://t.co/WiBCb3WAfV Case! #CAR

28 Dec 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.